Last update 21 Nov 2024

Temelimab (GeNeuro)

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-HERV-W humanized monoclonal antibodies(GeNeuro), Immunoglobulin G4, anti-(multiple sclerosis-associated retrovirus viral envelope protein) (human-mus musculus monoclonal gnbac1 heavy chain), disulfide with human-mus musculus monoclonal gnbac1 kappa-chain, dimer, Temelimab
+ [5]
Target
Mechanism
ERV env inhibitors(Envelope ERV derived genes inhibitors)
Originator Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple Sclerosis, Relapsing-RemittingDiscovery
IT
01 Apr 2016
Multiple Sclerosis, Relapsing-RemittingDiscovery
PL
01 Apr 2016
Multiple Sclerosis, Relapsing-RemittingDiscovery
DE
01 Apr 2016
Multiple Sclerosis, Relapsing-RemittingDiscovery
HR
01 Apr 2016
Multiple Sclerosis, Relapsing-RemittingDiscovery
RS
01 Apr 2016
Multiple Sclerosis, Relapsing-RemittingDiscovery
BG
01 Apr 2016
Multiple Sclerosis, Relapsing-RemittingDiscovery
RU
01 Apr 2016
Multiple Sclerosis, Relapsing-RemittingDiscovery
CZ
01 Apr 2016
Multiple Sclerosis, Relapsing-RemittingDiscovery
UA
01 Apr 2016
Multiple Sclerosis, Relapsing-RemittingDiscovery
ES
01 Apr 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
41
(Temelimab 18 mg/kg)
ljwuwkkukg(rfuufvbvtv) = snceoywbli qdmxydqvfh (qwiwoponxd, deabxuitlc - gjubipwjlx)
-
07 Nov 2024
(Temelimab 36 mg/kg)
ljwuwkkukg(rfuufvbvtv) = wjemkbsogv qdmxydqvfh (qwiwoponxd, ulhnzwxyvz - dnxzkjqyjj)
Phase 2
Multiple sclerosis relapse
serum neurofilament light chain (NfL) | glial fibrillary acidic protein (GFAP)
41
ajspccfhds(dvxsqenmxo) = gpvpgzwmvl nelxoaiqqt (ijynjfvqmi )
-
12 Oct 2022
ajspccfhds(dvxsqenmxo) = psemvgcouk nelxoaiqqt (ijynjfvqmi )
Phase 2
270
enufsnmckc(vdjydxrhzx): P-Value = 0.014
Negative
09 Jul 2021
Placebo
Phase 2
64
(zrluriazld) = Temelimab was well tolerated without any group difference in the frequency or severity of adverse events. kfgkcykgfm (ewxeipfamn )
Positive
01 Jul 2020
Placebo
Phase 2
270
dnmacwfzmy(mrrvfaxsdd) = qeukoqosbg uoalpukjsj (hfeabeannw )
Positive
10 Sep 2019
Comparator Group (originally randomized to placebo)
dnmacwfzmy(mrrvfaxsdd) = dqguadwaci uoalpukjsj (hfeabeannw )
Phase 1
24
(icdlfikvmk) = Temelimab was well tolerated, with no particular adverse drug reactions at any dos anptdxmkic (wpdgwbemkv )
Positive
01 Sep 2019
Placebo
Phase 2
270
(mbknysyrfp) = GNbAC1 18 mg/kg maintained myelin integrity through Week 48, as measured by Magnetization Transfer Ratio (MTR), in normal-appearing white matter and cerebral cortex sbekaltktk (qocucdvcnk )
Positive
07 May 2019
Phase 2
Multiple Sclerosis
MSRV-Env | TLR4 activation markers
260
kbwzxnabzu(xnpntjhqpm) = trwjkfxpzv zpklqnwfcl (leyxidbwsx )
-
05 Apr 2016
kbwzxnabzu(xnpntjhqpm) = msloipexcy zpklqnwfcl (leyxidbwsx )
Phase 2
10
(cadfvdejji) = GNbAC1 was well tolerated in all patients. ztfjwjohts (zlihcjmnyr )
Positive
01 Jun 2015
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free